Table 2.

Studies about difluprednate treatment for the management of uveitis or postoperative inflammation control.

Study and year	Study population	No. of patients	Mean age in years ± SD (range)	Difluprednate time	Clinically important IOP elevation*	Risk factors identified
Our study	Uveitis	54	40.4 ± 18.8 (5 – 79)	Mean 11.3 ± 9.9 weeks (1 – 44)	31.5%	Children Concurrent systemic steroid
Schallhorn et al. 2018	Uveitic macular edema	58 (72 eyes)	Median 45 (7 –92)	1 month	8 eyes (11%)
Kusne et al. 2016	Post-cataract surgery in adults	1337	70.6 ± 8.5	Range 5 – 10 days	4.4%	Older age (>75 years) Glaucoma history
Wilson et al. 2016	Post-cataract surgery in children	39	Range 0 – 3	4 weeks	5.1% (IOP >21 mmHg)
Jeng et al. 2014	Post-vitreoretinal surgery	100	64.9	Mean 41.6 days	35%
Sheppard et al. 2014	Endogenous anterior uveitis	56	49.9 ± 15.3 (11 – 87)	Mean 27.0 ± 7.1 days	16.1%
Slabaugh et al. 2012	Pediatric non-infectious uveitis	14	12 ± 3 (7 – 18)	Median 27 weeks (4 – 63)	50%**
Birnbaum et al. 2011	Uveitis	27	34 (6 – 63)	Mean 16.4 weeks (1 – 46)	52% (≥10 mmHg IOP increase)	Children
Donnenfeld et al. 2011	Post-cataract surgery in adults	59	70.5 (51 – 105)	2 weeks	1.7%
Foster et al. 2010	Endogenous anterior uveitis	50	46.5 ± 15.1	4 weeks	6%
Smith et al. 2010	Post-cataract surgery	81	69.4 ± 9.44 (44 – 86)	1 month	3.7%
Korenfeld et al. 2009	Post-ocular surgery in adults	218	Median 70 (24 – 88)	4 weeks	3%

^*Clinically important IOP elevation defined as having an IOP ≥21 mmHg and ≥10 mmHg increase from baseline at the same visit.

^**Clinically important IOP elevation defined as having an IOP ≥24 mmHg and ≥10 mmHg increase from baseline in this study.

IOP; Intraocular pressure, SD; Standard deviation.